Liver Cancer Diagnostics Market Scope And Analysis

  • Report Code : TIPRE00003017
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Liver Cancer Diagnostics Market Analysis, Trends, and Scope 2024 to 2031

Buy Now

Liver Cancer Diagnostics Market Report Liver Cancer Diagnostics Market Size and Share Liver Cancer Diagnostics Market Scope and Analysis

Liver Cancer Diagnostics Market Report Scope

Report Attribute Details
Market size in 2023 US$ 10.78 Billion
Market Size by 2031 US$ 20.57 Billion
Global CAGR (2023 - 2031) 8.4%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Type
  • Laboratory Tests
  • Endoscopy
  • Imaging
  • Biopsy
By End User
  • Hospitals and Diagnostic Laboratories
  • Academic and Research Institutes
  • CRO Laboratories
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Abbott
  • BioMerieux SA
  • F HOFFMANN LA ROCHE LTD
  • Illumina Inc
  • Koninklijke Philips N V
  • QIAGEN
  • Siemens Healthineers AG
  • THERMO FISHER SCIENTIFIC INC
  • GE Healthcare
  • Perspectum

    • Liver Cancer Diagnostics Market News and Recent Developments

    The liver cancer diagnostics market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the liver cancer diagnostics market are listed below:

    • Illumina, Inc. launched TruSight oncology test for assessing multiple tumor genes and biomarkers. The TruSight test will soon begin its global launch in Europe. It assesses the tumor genes and biomarkers to discover the specific molecular profile of a patient’s cancer, helping to inform precision medicine decisions. (Source: Illumina, Inc., Press Release, March 2022)
    • Perspectum entered a partnership with HepQuant to provide delivery of HepQuant’s liver function evaluation technology via Perspectum’s Contract Research Organization (CRO) services. This collaboration enabled pharmaceutical companies backing clinical trials for liver disease, including liver cirrhosis, non-alcoholic steatohepatitis (NASH), autoimmune liver diseases, and liver cancer to receive imaging and function testing knowledge from Perspectum’s Pharma Solutions. (Source: Perspectum, Press Release, November 2021)

    Liver Cancer Diagnostics Market Report Coverage and Deliverables

    The “Liver Cancer Diagnostics Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Liver cancer diagnostics market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Liver cancer diagnostics market trends, as well as market dynamics such as drivers, restraints, and key opportunities
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • Liver cancer diagnostics market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments3
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments in the liver cancer diagnostics market
    • Detailed company profiles